The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 124 participants.

Also called NCT04573049

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 124 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04573049
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04573049. Randomized; quadruple masking; primary purpose prevention. Start 2020-09-01 (actual); primary completion 2022-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
Condition
Aortic Valve Stenosis
Condition
Heart Failure
Condition
Inotropic Agents
Condition
Safety Issues
Condition
Effect of Drug
Condition
Cardiac Event
Intervention (Drug)
Levosimendan
Intervention (Other)
Placebo
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)
Collaborator
China International Medical Foundation (class: other)

Record details

Record id
cardio:ct-nct04573049
Content hash
80a108fb4736644a9d0f26ba79e16936f573b0b988e96c3f27b1edf17b1e63b7